Compare SA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SA | KOD |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2004 | 2018 |
| Metric | SA | KOD |
|---|---|---|
| Price | $25.71 | $41.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $65.00 | $35.43 |
| AVG Volume (30 Days) | 607.0K | ★ 858.4K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.11 | $4.60 |
| 52 Week High | $40.06 | $47.84 |
| Indicator | SA | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 61.86 |
| Support Level | $24.09 | $39.37 |
| Resistance Level | $32.47 | $46.72 |
| Average True Range (ATR) | 1.35 | 3.19 |
| MACD | 0.03 | 0.63 |
| Stochastic Oscillator | 34.89 | 80.61 |
Seabridge Gold Inc is a development-stage company involved in the exploration and development of gold properties situated in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.